VWF/FVIII concentrates in high-risk immunotolerance: The RESIST study

Haemophilia

Volumn 13, Issue SUPPL. 5, 2007, Pages 73-77

  Gringeri, Alessandro ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Factor VIII; Haemophilia A; Immune tolerance induction; Inhibitors; Prognostic factors; Von Willebrand factor

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 8; VON WILLEBRAND FACTOR;

ARTICLE; CLINICAL TRIAL; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HEALTH CARE COST; HEMOPHILIA A; HIGH RISK PATIENT; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGNOSIS;

COAGULANTS; FACTOR VIII; HEMOPHILIA A; HUMANS; IMMUNE TOLERANCE; ISOANTIBODIES; PROSPECTIVE STUDIES; RESEARCH DESIGN; VON WILLEBRAND FACTOR;

EID: 37149006720     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2007.01579.x     Document Type: Article

References (21)

1. Brackmann HH, Gormsen J. Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder. Lancet 1977; 2: 933.
2. DiMichele DM, Kroner BL. Analysis of the North American Immune Tolerance Registry (NAITR) 1993-1997: Current practice implications. ISTH Factor VIII/IX Subcommittee Members. Vox Sang 1999; 77 (Suppl. 1): 31-2.
3. Mariani G, Kroner B. Immune tolerance in hemophilia with factor VIII inhibitors: Predictors of success. Haematologica 2001; 86: 1186-93.
4. Lenk H. The German Registry of immune tolerance treatment in hemophilia -1999 update. Haematologica 2000; 10 (Suppl.): 45-7.
5. Haya S, Lopez MF, Aznar JA, Batlle J. Immune tolerance treatment in haemophilia patients with inhibitors: The Spanish Registry. Haemophilia 2001; 7: 154-9.
6. Di Michele DM. Immune tolerance: A synopsis of the international experience. Haemophilia 1998; 4: 568-73.
7. Hay CR. Immune tolerance induction: Prospective clinical trials. Haematologica 2000; 85 (10 Suppl.): 52-6.
8. Astermark J, Morado M, Rocino A et.al. Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors. Haemophilia 2006; 12: 363-71.
9. DiMichele DM. Immune tolerance: Critical issues of factor dose, purity and treatment complications. Haemophilia 2006; 12 (Suppl. 6): 81-5.
10. Berntorp E, Ekman M, Gunnarsson M, Nilsson IM. Variation in factor VIII inhibitor reactivity with different commercial factor VIII preparations. Haemophilia 1995; 2: 95-9.
11. Amano K, Arai M, Koshihara K et.al. Autoantibody to factor VIII that has less reactivity to factor VIII/von Willebrand factor complex. Am J Hematol 1995; 49: 310-7.
12. Suzuki T, Arai M, Amano K, Kagawa K, Fukutake K. Factor VIII inhibitor antibodies with C2 domain specificity are less inhibitory to factor VIII complexed with von Willebrand factor. Thromb Haemost 1996; 76: 749-54.
13. Kallas A, Talpsep T. von Willebrand factor in factor VIII concentrates protects against neutralization by factor VIII antibodies of haemophilia A patients. Haemophilia 2001; 7: 375-80.
14. Gensana M, Altisent C, Aznar JA et.al. Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors with factor VIII. Haemophilia 2001; 7: 369-74.
15. Astermark J, Voorberg J, Lenk H et.al. Impact of inhibitor epitope profile on the neutralizing effect against plasma-derived and recombinant factor VIII concentrates in vitro. Haemophilia 2003; 9: 567-72.
16. Lin Y, Yang X, Chevrier MC et.al. Relationships between factor VIII: Ag and factor VIII in recombinant and plasma-derived factor VIII concentrates. Haemophilia 2004; 10: 459-69.
17. Salvagno GL, Astermark J, Ekman M et.al. Impact of different inhibitor reactivities with commercial factor VIII concentrates on thrombin generation. Haemophilia 2007; 13: 51-6.
18. Auerswald G, Spranger T, Brackmann HH. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients. Haematologica 2003; 88: EREP05.
19. Kreuz W, Ettingshausen CE, Auerswald G et.al. Epidemiology of inhibitors and current treatment strategies. Haematologica 2003; 88: EREP04.
20. Orsini F, Rotschild C, Beurrier P, Faradji A, Goudemand J, Polack B. Immune tolerance induction with highly purified plasma-derived factor VIII containing von Willebrand factor in hemophilia A patients with high-responding inhibitors. Haematologica 2005; 90: 1288-90.
21. Gringeri A, Musso R, Mazzucconi MG et.al. Immune tolerance induction with a high-purity VWF/FVIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response. Haemophilia 2007, in press.